Immunic Inc. (NASDAQ: IMUX) has completed a registered direct offering, raising approximately $5.1 million to support its ongoing clinical development programs. The biotechnology company secured funding through the sale of 5,666,667 common shares at $0.90 per share, with Aberdeen Investments leading the investment round.
The newly raised capital will primarily fund the company's clinical trials and operational expenses. Immunic is currently developing a portfolio of orally administered small molecule therapies targeting chronic inflammatory and autoimmune diseases, with a particular focus on multiple sclerosis and gastrointestinal conditions.
The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis. The therapy has demonstrated promising therapeutic activity in previous clinical trials, offering potential neuroprotective effects and anti-inflammatory properties.
In addition to its multiple sclerosis program, Immunic is advancing two other promising therapeutic candidates. IMU-856 targets the SIRT6 protein and aims to restore intestinal barrier function, potentially addressing conditions like celiac disease, inflammatory bowel disease, and graft-versus-host disease. IMU-381, still in preclinical testing, represents a next-generation molecule focused on gastrointestinal disease treatment.
This funding provides Immunic with critical resources to continue advancing its innovative therapeutic pipeline, potentially offering new treatment options for patients suffering from complex inflammatory and autoimmune conditions.
